Overview The NIAMS Clinical Trial Working Group was established to consider how the institute could optimally solicit and fund applications for clinical trials that would have the greatest impact in improving clinical outcomes, whether of rare or common diseases, for people with diseases and/or conditions within the NIAMS mission. Please

The National Institutes of Health Loan Repayment Program (LRP) is designed to recruit and retain highly qualified health professionals into biomedical or biobehavioral research careers.

This document PDF format ( 747 KB) Prepared by the National Institute of Arthritis and Musculoskeletal and Skin Diseases December 22, 2015 Contents Introduction Chapter 1: Etiology and Prevention Genetics and Genomics Environment Epidemiology Chapter 2: Mechanisms of Disease Immune and Inflammatory Mechanisms Target Organ Damage Chapter 3: New Treatments

The Accelerating Medicines Partnership® Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) program launched in 2014 as one of the original components of the Accelerating Medicines Partnership (AMP).

Cómo vivir con artritis: Información básica de salud para usted y su familia (Living With Arthritis: Health Information Basics for You and Your Family)

PREFACE Investigators should consider using this template when developing the Data and Safety Monitoring Plan (DSMP) for clinical studies funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The goal of the DSMP is to provide a general description of a plan that you intend to